MPN News from 2022 EHA Congress

  • MPNRF | June 27, 2022

    A number of important findings regarding MPNs were featured in June, at the European Hematology Association’s (EHA2022) Congress in Vienna. Some key highlights follow.

    How to select patients with myelofibrosis for transplantation and how to manage MF patients during a transplant procedure.  

    Jean Jacques Kiladjian, Pr, MD, PhD, Hospital Saint-Louis and INSERM, Paris.

    Pegylated interferon-alfa found to control the differentiation of blood stem cells in MPNs, which could lead to new treatments to stop this process. 

    Anna S Nam, MD, Weill Cornell Medicine, New York. 

    National quality of life survey across MPNs shows areas of patient/physician relationship needed improvement

    Tatiana Ianova, Multinational Center for Quality of Life Research, St. Petersburg.

    Evaluation of the prognostic value of thrombophilia markers in patients with MPNs shows how some predictive biomarkers could be helpful to understand and inhibit MPN progression.

    Abstract not yet available.

    Tatyana Makarik, National Research Center for Hematology, Moscow.

    Mutational studies elucidate differences and intersections of MPNs and myelodysplastic syndrome (MDS), which could lead to more accurate diagnosis and choice of treatment for these patients.

    Alejandro Pita, MD, University Hospital of Salamanca, Spain.